JCN Newswire
TOKYO, August 18, 2025 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the in-house discovered and developed orexin receptor antagonist DAYVIGO® (brand name in China: “DAYVIGO®“ generic name: lemborexant) has launched in China for the treatment of adults with insomnia…
Read More
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China
Buffy Mayoral
03:23
TOKYO, August 18, 2025 – (JCN Newswire) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the in-house discovered and developed orexin receptor antagonist DAYVIGO® (brand name in China: “DAYVIGO®“ generic name: lemborexant) has launched in China for the treatment of adults with insomnia…
